Neil Osterweil

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first patient in the phase 3 OlympiA trial was enrolled.

SAN ANTONIO — Nearly 10 years along patients with high-risk BRCA -positive breast cancers who had been treated with the poly(ADP-ribose) polymerase (PARP) inhibitor

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving

Both radiotherapy and endocrine therapy are good single-modality options for women 70 years or older with early, favorable risk breast cancer, but patients report better quality of life after radiation.

SAN ANTONIO — The randomized phase 3 ZEST trial, which was aimed at evaluating niraparib (Zejula) for prevention or delay of breast cancer recurrence

Deterioration-free rates at 1 year were comparable for patients with or without brain metastases.

SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether

An analysis of secondary outcomes in the SONIA trial showed that adverse events with CDK4/6 inhibitors were similar regardless of treatment timing.

SAN ANTONIO — More than half of patients with pretreated HER2-positive advanced or metastatic breast cancer who received the antibody-drug conjugate

March 5, 2014 | Dermatology Author and Disclosure Information FROM CROI 2014